-
|
Reuters –
4:03 PM ET 12/08/2020
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES TO WIND-DOWN MICROBIOME PROGRAM. * Assembly Biosciences Inc (ASMB) - WIND-DOWN ITS MICROBIOME PROGRAM. * Assembly Biosciences Inc (ASMB) - TO PRIORITIZE RESOURCES AND FOCUS ON ADVANCEMENT OF ITS PIPELINE OF NOVEL CORE INHIBITORS FOR CHRONIC HBV.
|
-
|
GlobeNewswire –
4:02 PM ET 12/08/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.
|
-
|
GlobeNewswire –
4:30 PM ET 12/04/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to three new employees to purchase an aggregate of 14,520 shares of the Companys common stock with an exercise price of $5.66 per share, the closing price of Assembly Bios common s...
|
-
|
GlobeNewswire –
8:00 AM ET 11/17/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing.
|
-
|
Reuters –
8:48 AM ET 11/16/2020
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES AND DOOR PHARMACEUTICALS SIGN COLLABORATION AND OPTION AGREEMENT TO DEVELOP A NOVEL CLASS OF HBV CORE PROTEIN MODULATORS Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 11/16/2020
Assembly Biosciences (ASMB), Inc. and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus core protein modulators.
|
-
|
GlobeNewswire –
8:00 AM ET 11/13/2020
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline - SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases assoc...
|
-
|
GlobeNewswire –
4:30 PM ET 11/06/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Companys common stock with an exercise price of $14.75 per share, the closing price of Assemblys common stock on November 2, 2020.
|
-
|
Reuters –
4:35 PM ET 11/05/2020
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE. * Q3 LOSS PER SHARE $0.09. * Q3 EARNINGS PER SHARE ESTIMATE $-0.75 -- REFINITIV IBES DATA. * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $237.9 MILLION AS OF SEPTEMBER 30, 2020.
|
-
|
Reuters –
4:03 PM ET 11/05/2020
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES PROVIDES UPDATE ON THE ONGOING PHASE 2 EXTENSION STUDY OF VEBICORVIR IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. * Assembly Biosciences Inc (ASMB) - STUDY HAS NOT ACHIEVED MEANINGFUL SVR RATES AS 39 OF 41 PATIENTS HAVE NOW RELAPSED.
|
-
|
GlobeNewswire –
4:02 PM ET 11/05/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today reported financial results and a business update for the third quarter ended September 30, 2020.
|
-
|
GlobeNewswire –
4:01 PM ET 11/05/2020
- HBV fields first core inhibitor combination study to assess off-treatment response has not achieved a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program remains on track to initiate in H1 2021 for chronic suppressive therapy -- Assembly Bio to host conference call today at 5:00 p.m. ET - SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 -- Assembly Bioscie...
|
-
|
GlobeNewswire –
8:00 AM ET 11/02/2020
- Four posters, including two late breaking, will include new clinical and preclinical data on Assembly Bio’s hepatitis B virus core inhibitor portfolio SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 -- Assembly Biosciences (ASMB), Inc. , a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced that data...
|
-
|
GlobeNewswire –
8:00 AM ET 10/20/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors.
|
-
|
GlobeNewswire –
8:00 AM ET 10/15/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced that John McHutchison AO, MD the companys CEO and president was named the recipient of the Advance 2020 Global Impact award.
|
-
|
GlobeNewswire –
7:30 AM ET 10/05/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020Panel: What are the virological and immunological gaps that need to be addressed?
|
-
|
GlobeNewswire –
4:30 PM ET 10/02/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Companys common stock with an exercise price of $17.29 per share, the closing price of Assemblys common stock ...
|
-
|
GlobeNewswire –
4:30 PM ET 09/04/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, today announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Companys common stock with an exercise price of $20.14 per share, the closing price of Assemblys common stock...
|
-
|
GlobeNewswire –
6:00 AM ET 08/28/2020
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Co...
|
-
|
GlobeNewswire –
8:00 AM ET 08/27/2020
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 -- Assembly Biosciences, Inc. (ASMB) and Arbutus Biopharma Corporation (ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assemblys lead hepatitis B virus core inhibitor candidate ABI-H0731 in combination with Arbutus proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-ca...
|
Page:
|
Today's and Upcoming Events
-
ASMB to announce Q4 earnings (Unconfirmed)
Past Events (last 90 days)
-
ASMB announced Q3 earnings.
Data provided by Thomson Reuters © 2021
|